The increase in demand for Ozempic as a weight-loss aid has led to nationwide shortages of the drug, which wasnt solved until February 2025
Weight loss goals and expectations : NICE guidance (TA875) supports the use of semaglutide 2.4 mg (Wegovy) for weight management in adults with at least one weight-related comorbidity and a BMI of at least 35 kg/m (or at least 30 kg/m for people from certain ethnic backgrounds), as part of a specialist weight management service
Whilst not experienced by everyone, dizziness is recognised as an uncommon side effect, affecting up to 1 in 100 people according to Medicines and Healthcare products Regulatory Agency (MHRA) approved product information
Puede que suene a una utopa, pero todos pueden llevar una vida ms saludable, lo cual mejorar las cosas para la sociedad en su conjunto.
[DOI] [PubMed] [Google Scholar] 596.Arnold LM, McCarberg BH, Clair AG, et al
Booking Your Semaglutide Treatment Ready to transform your health